Hepeng Shi, Avistone CEO
December 8, 2021 07:05 AM EST
Financing
China

Vi­vo Cap­i­tal, Bain, Pri­mav­era pour $200M in­to vir­tu­al­ly un­known tar­get­ed on­col­o­gy play out of Chi­na

Amber Tong

Hong­bo Lu was a board mem­ber at Crown­Bio, a pre­clin­i­cal on­col­o­gy CRO, when a lo­cal com­pa­ny — so lo­cal it didn’t even have an Eng­lish name …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

What will phar­ma's share buy­back shop­ping spree mean for M&A?

Pfiz­er’s prostate can­cer da­ta leak shows promis­ing re­sults in ear­ly-stage study

No­var­tis re­turns for its an­ti­co­ag­u­lant in up to $3.1B buy of Black­stone’s An­thos

IN8bio’s Phase 1 AML da­ta; Lay­offs at Q32 Bio and Third Har­mon­ic

In­ven­ti­va cuts pipeline, lays off near­ly en­tire re­search team in bid to get to Phase 3 MASH read­out

sponsored

Re­duc­ing risk in drug de­vel­op­ment: The im­por­tance of val­i­dat­ed MRD test­ing in lym­phoid can­cers

A service from the Financial Times